Browse the evidence

Intranasal delivery of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could overcome the limitations of subcutaneous administration for obesity treatment.

Practitioners should consider intranasal delivery methods for improving patient adherence and reducing side effects.

Innovative approaches for nasal delivery of GLP-1 RAs show promising preclinical results.

Practitioners should consider these innovative approaches to enhance the effectiveness of GLP-1 RA delivery.

The incidence of obesity-related glomerulopathy has increased 10-fold in recent years.

Awareness of obesity-related kidney issues is essential for healthcare providers.

Intentional weight loss can increase health risk in the long-term due to the release of persistent organic pollutants (POPs) from adipose tissue.

Practitioners should consider the potential long-term health risks associated with weight loss due to POP exposure.

Chronic exposure to low levels of POPs is a new risk factor for common metabolic and cardiovascular diseases.

Awareness of POPs as a risk factor can guide health interventions and weight management strategies.

The release of POPs during weight loss may have harmful effects that are opposite to the expected benefits of losing weight.

Weight loss strategies should consider the potential negative impacts of POP release.

There is no strong evidence that there is an optimal ratio of macronutrients for improving glycaemic control or reducing cardiovascular risk.

Practitioners should be cautious in recommending specific macronutrient ratios for diabetes management.

GB participants used fewer glucose-lowering medications at 10 years, but HbA1c, fasting glucose, calculated cardiovascular risk, quality-of-life, and incident diabetes complications did not differ significantly between the groups.

While GB surgery may reduce the need for glucose-lowering medications, it does not significantly improve other health metrics.

Indirect calorimetry is the favored method to assess human energy expenditure and is the only method enabling the assessment of macronutrient oxidation.

Practitioners should consider using indirect calorimetry for accurate assessment of energy expenditure and macronutrient oxidation.

The doubly labeled water method provides accurate assessment of human energy expenditure under free living conditions.

Practitioners can use the doubly labeled water method for accurate energy expenditure assessments in free living individuals.

Calculations from oxygen consumption and carbon dioxide production can provide erroneous results when several biochemical pathways are engaged.

Practitioners should be cautious when interpreting energy expenditure calculations, especially when multiple metabolic pathways are involved.

Obesity accompanies an increasing burden of metabolic disease among people living with HIV (PWH).

Healthcare providers should be aware of the increased risk of metabolic diseases in PWH with obesity.

Contemporary antiretroviral therapy (ART) regimens, particularly integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF), are contributors to weight gain and obesity in PWH.

Clinicians should consider the impact of specific ART regimens on weight management in PWH.

Metabolic dysregulation is linked to ectopic fat deposition and alterations in immune cell populations in adipose tissue among PWH.

Understanding these links can help in developing targeted interventions for obesity in PWH.

There is a lack of evidence on the efficacy of various methodologies used by physique competitors to improve body composition.

Practitioners should be cautious about methodologies lacking evidence.

Semaglutide may improve wait-list times for renal transplantation by overcoming obesity as a barrier.

Addressing obesity in patients may facilitate their eligibility for renal transplantation.

Gender, household size, and education were associated with GLP-1 use and interest.

Marketers should consider demographic factors when targeting potential GLP-1 consumers.

The therapeutic efficacy of poly-agonists is likely to change the treatment paradigm for obesity.

Healthcare providers may need to adapt to new treatment protocols involving poly-agonists.

The use of medications for obesity will likely require lifelong treatment.

Practitioners should prepare for long-term management strategies when prescribing obesity medications.

Persistence in the OMM-eligible cohort was 73.8%.

High persistence rates suggest good adherence to tirzepatide among eligible patients.

Real-world evidence suggests slower tirzepatide dose escalation than in clinical trials.

Practitioners may need to adjust expectations regarding dose escalation in real-world settings.

NAFLD should be understood as part of a systemic disease characterized by abnormal fat accumulation in tissues other than adipose tissue.

Understanding NAFLD as a systemic disease can improve patient management strategies.

DTC genetic tests are marketed with faux scientific authority, potentially confusing consumers.

Practitioners should help consumers navigate the complexities of DTC genetic test marketing.

Obesity is projected to affect approximately half the US population by the year 2035.

Practitioners should be aware of the increasing prevalence of obesity for public health planning.